Statin Therapy and the Risk of COVID-19: A Cohort Study of the National Health Insurance Service in South Korea
- PMID: 33578937
- PMCID: PMC7916713
- DOI: 10.3390/jpm11020116
Statin Therapy and the Risk of COVID-19: A Cohort Study of the National Health Insurance Service in South Korea
Abstract
We aimed to investigate whether statin therapy is associated with the incidence of coronavirus disease 2019 (COVID-19) among the South Korean population. In addition, we examined whether statin therapy affects hospital mortality among COVID-19 patients. The National Health Insurance Service (NHIS)-COVID-19 database in South Korea was used for data extraction for this population-based cohort study. A total of 122,040 adult individuals, with 22,633 (18.5%) in the statin therapy group and 101,697 (91.5%) in the control group, were included in the analysis. Among them, 7780 (6.4%) individuals were diagnosed with COVID-19 and hospital mortality occurred in 251 (3.2%) COVID-19 cases. After propensity score matching, logistic regression analysis showed that the odds of developing COVID-19 were 35% lower in the statin therapy group than in the control group (odds ratio: 0.65, 95% confidence interval: 0.60 to 0.71; p < 0.001). Regarding hospital mortality among COVID-19 patients, the multivariable model indicated that there were no differences between the statin therapy and control groups (odds ratio: 0.74, 95% confidence interval: 0.52 to 1.05; p = 0.094). Statin therapy may have potential benefits for the prevention of COVID-19 in South Korea. However, we found that statin therapy does not affect the hospital mortality of patients who are diagnosed with COVID-19.
Keywords: hospital mortality; hydroxymethylglutaryl-CoA reductase inhibitors; infections.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- Eggmann S., Luder G., Verra M.L., Irincheeva I., Bastiaenen C.H.G., Jakob S.M. Functional ability and quality of life in critical illness survivors with intensive care unit acquired weakness: A secondary analysis of a randomised controlled trial. PLoS ONE. 2020;15:e0229725. doi: 10.1371/journal.pone.0229725. - DOI - PMC - PubMed
-
- Moore J.T., Ricaldi J.N., Rose C.E., Fuld J., Parise M., Kang G.J., Driscoll A.K., Norris T., Wilson N., Rainisch G., et al. Disparities in Incidence of COVID-19 Among Underrepresented Racial/Ethnic Groups in Counties Identified as Hotspots During June 5–18, 2020—22 States, February–June 2020. MMWR Morb. Mortal. Wkly. Rep. 2020 Jun 5;69:1122. doi: 10.15585/mmwr.mm6933e1. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
